Details of Disease

General Information of Disease (ID: DISAB5B8)

Disease Name Advanced malignancy
Disease Class 2A00-2F9Z: Solid tumour/cancer
Disease Hierarchy
DIS01GPL: Grass pollen hypersensitivity
DISAB5B8: Advanced malignancy
ICD Code
ICD-11
ICD-11: 2A00-2F9Z

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 21 Clinical Trial Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
MLN4924 DMP36KD Phase 3 Small molecular drug [1]
Napabucasin DMDZ6Q3 Phase 3 NA [2]
CX-072 DMVZT2I Phase 2 Antibody [3]
INCAGN01949 DMK7OHI Phase 2 Antibody [4]
KN035 DMKLMG6 Phase 2 Antibody [3]
MCS-110 DM0CL4I Phase 2 NA [2]
INCB53914 DMKMSP2 Phase 1/2 NA [2]
INCB57643 DMBGU7V Phase 1/2 NA [2]
BI-754091 DM3JOIX Phase 1 Monoclonal antibody [3]
FS118 DM0QH9K Phase 1 Antibody [2]
IDH305 DMNWPMO Phase 1 NA [2]
LY3300054 DMOV2ML Phase 1 Monoclonal antibody [3]
LZM009 DMHDCSL Phase 1 Monoclonal antibody [3]
MSB2311 DMH8VXE Phase 1 Monoclonal antibody [3]
PF-06801591 DMDE9I6 Phase 1 Antibody [3]
Sym021 DMVXLS5 Phase 1 Monoclonal antibody [3]
TAB001 DMRHBRD Phase 1 NA [2]
TAK-701 DML3M0O Phase 1 Small molecular drug [5]
TSR-042 DM56PFL Phase 1 Monoclonal antibody [3]
XL999 DMYS13R Phase 1 NA [6]
XmAb20717 DMJIH83 Phase 1 Antibody [3]
------------------------------------------------------------------------------------
⏷ Show the Full List of 21 Drug(s)

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

References

1 Drug discovery: Fresh target for cancer therapy. Nature. 2009 Apr 9;458(7239):709-10.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730.
4 ClinicalTrials.gov (NCT02923349) A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors. U.S. National Institutes of Health.
5 ClinicalTrials.gov (NCT00831896) Phase I Study of TAK-701 in Adult Patients With Advanced Nonhematological Malignancies. U.S. National Institutes of Health.
6 Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.